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It is hypothesized that cancer stem cells arise either from normal stem cells or from progenitor cells that have 
gained the ability to self-renew. Here we determine whether mammary cancer stem cells can be isolated by using 
antibodies that have been used for the isolation of normal mammary stem cells. We show that BRCA1 mutant 
cancer cell lines contained a subpopulation of CD24+CD29+ or CD24+CD49f+ cells that exhibited increased 
proliferation and colony forming ability in vitro, and enhanced tumor-forming ability in vivo. The purified 
CD24+CD29+ cells could differentiate and reconstitute the heterogeneity found in parental cells when plated as a 
monolayer. Under low-attachment conditions, we detected “tumorspheres” only in the presence of double 
positive cells, which maintained their ability to self-renew. Furthermore, CD24+CD29+ cells could form tubular 
structures reminiscent of the mammary ductal tree when grown in three-dimensional cultures, implying that 
these cancer cells maintain some of the characteristics of the normal stem cells. Nevertheless, they could still drive 
tumor formation since as low as 500 double positive cells immediately after sorting from BRCA1 mutant primary 
tumors were able to form tumors with the same heterogeneity found in the original tumors. These data provide 
evidence that breast cancer stem cells originate from normal stem cells and advance our understanding of 
BRCA1-associated tumorigenesis with possible implications for future cancer treatment. 
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1. Introduction 
Breast cancer occurs at a high frequency and is 
the second leading cause of death from cancer in 
women [1, 2, 3, 4, 5]. One of the major problems in 
treating breast cancer is the heterogeneity of tumors 
that prevents a complete response of cancer cells to the 
treatment [6]. This situation is more evident especially 
in basal and breast cancer associated gene-1 
(BRCA1)-related breast cancers. The apparent paradox 
is that despite the excellent initial response to 
chemotherapy [7], cancer is more likely to recur early 
[8]. Clinical treatment regimens operate under the 
assumption that all cancer cells have equal malignant 
potential, thus, suffer from their lack of specificity for 
only tumorigenic cells. Relatively successful cancer 
treatments shrink the bulk of tumor cells but often fail 
to eliminate the cancer stem cells [9]. The necessity for 
targeting cancer stem cells highlights the importance 
of defining markers for identification of the cancer 
initiating subpopulation of cells in order to better 
characterize and analyze these cells. 
There are two possible ways in which cancer stem 
cells can be generated. They can arise either from 
normal stem cells or from progenitor cells that have 
gained the ability for self-renewal. In contrast to the 
progress in the hematopoietic system, where the entire 
cellular hierarchy is known [10, 11], our knowledge on 
mammary tissue is limited. The massive expansion of 
the mammary gland during puberty and pregnancy, 
together with the regenerative capacity during 
successive reproductive cycles implicate the presence 
of stem-like cells in the mammary gland [12]. In the 
adult human breast it was shown that staining for 
keratins K14 and K19 may reveal both the stem cell 
ductal zone and the stem cell hierarchy [13]. In mice, 
the existence of normal mammary stem cells has been 
postulated in the past by experiments showing that 
after serial transplantation of retrovirally tagged 
epithelial fragments, a single progenitor cell may 
repopulate an entire mammary gland [14]. More 
recently, discrete populations of mouse mammary 
cells have been isolated on the basis of cell-surface 
markers and a subpopulation (Lin-CD29hiCD24+ or 
Lin-CD49fhiCD24med) was identified that is highly Int. J. Biol. Sci. 2008, 4 
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enriched for mammary stem cells [15, 16]. On the other 
hand, a population of Lin-CD44+CD24-/Low cells has 
been identified as cancer stem cells in human breast 
cancers [17]. Although there has been much progress 
in the field, many questions still remain. For example, 
can we use markers for normal mammary stem cells in 
mice to isolate mammary cancer stem cells? Is it 
possible that markers for identifying human breast 
cancer stem cells can be used for the isolation of either 
m a m m a r y  c a n c e r  s t e m  c e l l s  o r  n o r m a l  b r e a s t  s t e m  
cells? What are the phenotypes of these cells by means 
of the particular used markers for cancer stem cells, 
normal mammary stem cells, and the progenitor cells? 
These undefined issues are multiplied when 
considering the role of BRCA1 in mammary stem cells. 
Germline mutations in BRCA1 have been detected in 
approximately half of familial breast cancer cases and 
most cases of combined familial breast/ovarian 
cancers [1-3, 5, 18]. Numerous previous studies in 
mouse models uncovered an essential role for BRCA1 
in multiple biological processes, including DNA 
damage repair, cell cycle checkpoint regulation, 
transcriptional activation and repression, mammary 
gland development and mammary tumor formation 
[19]. Interestingly, many characteristics of the 
BRCA1-related cancers fit with the stem cell origin of 
these cancers. First, data suggests that breast stem cells 
are estrogen receptor negative [20] and breast cancers 
related to BRCA1 are more likely to be estrogen 
receptor negative than other types of breast cancer 
[21-23]. Indeed, it was recently shown that BRCA1 
plays a critical role in the differentiation of 
ER-negative stem/progenitor cells to ER-positive 
luminal cells [23]. Second, immortal cells, such as stem 
cells, need few mutational “hits” to become cancer, 
and this might explain the early age of onset of 
BRCA1-related cancers [24]. Third, women with 
BRCA1 mutations who breastfed for a cumulative total 
of more than one year have a statistically significant 
reduced risk of breast cancer, which is in accordance 
with the breast cancer stem cell phenotype [25].  
Taking into consideration that in the 
hematopoietic system normal stem cells share the 
same cell-surface markers with leukemic stem cells [26, 
27], we wanted to test whether CD24 and CD29, which 
have been used before for the isolation of normal 
mammary stem cells [15, 16], can be used as markers 
for the isolation of enriched subpopulations of cancer 
initiating cells. Moreover, our goal was to examine 
whether BRCA1 related mammary tumors contain 
CD24+CD29+ cells, which retain their capacity for 
self-renewal and tumor formation. Focusing on the 
isolation and characterization of breast cancer stem 
cells may be important in gaining a better 
understanding of cancer formation and the distinct 
nature of BRCA1-associated breast cancer.  
2. Materials and Methods  
Mice and cell culture 
Mice carrying Cre-LoxP mediated mammary 
specific deletion of the full length form of BRCA1 and 
a heterozygous null mutation of p53 
(Brca1Co/Co;p53+/-;MMTV-Cre) were generated as 
described earlier [28, 29] and maintained in a pathogen 
free facility. Cell lines were generated from tumors of 
either the third (W780) or fourth (W0069) mammary 
gland as reported previously [30]. Subclones were 
generated by a limiting dilution method. Briefly, 
W0069 cells were diluted (1 cell in 200 μl) and plated in 
96-well plates. Colonies were grown from single cells 
and expanded by plating them sequentially in 24-well, 
12-well, 6-well plates and finally in 10 cm dishes after 
trypsinization. All cells were grown in DMEM 
medium supplemented with 10% fetal bovine serum at 
37oC in a 5% CO2 incubator. Cells at 80-85% confluence 
were trypsinized, washed with PBS and plated for 
each experiment. 
Single-cell preparation and Lin depletion 
Mammary tumors from BRCA1 conditional 
k n o c k o u t  m i c e  w e r e  m i n c e d ,  w a s h e d  i n  P B S  a n d  
digested in DMEM containing 300 U/ml collagenase 
(Sigma) and 100 U/ml hyaluronidase (Sigma) for 1 
hour at 37oC. The resultant organoid suspension was 
sequentially resuspended in 0.25% trypsin-EDTA for 
1–2 min, 5 mg/ml dispase (Roche Diagnostics) and 0.1 
mg/ml DNase (Worthington) for 5 min, and 0.64% 
NH4Cl for 3 min before filtration through a 40-mm 
mesh to obtain single-cell suspension. Enrichment of 
Lin- epithelial cells was achieved through selective 
depletion of hematopoietic and endothelial cells using 
specific antibodies. Briefly, the single cell suspension 
was blocked in rat γ-globulin (Jackson Laboratories) 
and anti-CD16/CD32 Fcγ III/II receptor antibody (BD 
Pharmingen) for 10 min. Biotinylated antibodies 
against endothelial cells (anti-CD31, BD Pharmingen) 
and hematopoietic cells (anti-CD45 and anti-TER119, 
BD Pharmingen) were added for 25 min at 4oC. 
Subsequently, cells were incubated with anti-Biotin 
Microbeads and depleted by using MACS columns 
according to the manufacturer (Miltenyi Biotec Inc.). 
In case of cell lines in culture, cells were plated in 
10 cm dishes, trypsinized and filtered through a 
40-mm mesh or passed through 26G needles to obtain 
single-cell suspension followed by blocking as 
described above.   
FACS analysis  
Cells were stained at a concentration of 1x106 cells Int. J. Biol. Sci. 2008, 4 
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per 100 μl of buffer (PBS pH 7.2, 0.5% BSA, 2 mM 
EDTA). Antibodies against CD24 (anti CD24-PE, BD 
Pharmingen), CD29 (anti CD29-FITC, Chemicon) and 
CD49f (anti CD49f-FITC, BD Pharmingen) were used. 
Antibody incubations were performed at 4oC for 25 
min. Fluorescence-activated cell sorting (FACS) 
analysis was done using FACSCalibur flow cytometer 
(Becton Dickinson). Live single cells were gated for 
analysis. Cell sorting was carried out using FACSAria 
Cell Sorter (Becton Dickinson). 
Cell proliferation assays 
Cell proliferation was measured either by MTT 
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide] or growth curve assay. For the MTT assay, 
1–2x104 cells were plated per one well of a 24-well 
plate and medium was changed every 24 h. After 24 h, 
48 h and 72 h, medium was removed and 0.3 ml of 
0.1% MTT in PBS was added in each well. After 
incubation for 30 min in a 37°C CO2 incubator, MTT 
solution was removed and 0.8 ml of 2-propanol was 
added. After shaking for 30 min, OD560 was measured 
using a plate reader. Plating for each time point was 
done in triplicate. For the growth curve assay, 5x104 
cells were plated per one well of a 6-well plate and 
medium was changed every 24 h. Plate was incubated 
at 37oC in 5% CO2 and every 24 h cells were detached 
by trypsinization and counted with a Z1 Coulter 
counter. Plating for each time point was done in 
triplicate.  
In vitro colony assays 
For colony assays, cells were plated into wells of 
either 6-well plates or 24-well plates. For soft agar 
assay, a bottom layer of 0.5% agar in enriched medium 
(containing FBS, glutamine and antibiotics) was 
poured first, after solidifying this was followed by a 
layer containing a lower amount of agar (0.3%) and 
containing a specified number of cells (500 cells/well). 
The plates were placed in the incubator and after 
two-three weeks, colonies were counted by naked 
eyes. For three-dimensional assays, cells were 
resuspended in matrigel by following the thick gel 
method according to the manufacturer. Cells were 
allowed to set before covering with culture medium. 
Pictures of the colonies were taken after two weeks by 
using an Olympus IX81 inverted microscope. 
Histology and immunohistochemical staining 
For histology, tissues were fixed in 10% formalin, 
blocked in paraffin, sectioned, stained with 
hematoxylin and eosin, and examined by light 
microscopy. Detection of mitotic cells was performed 
using a ZYMED Histostain staining kit (ZYMED, San 
Francisco, CA) according to the manufacturer's 
instructions by using a primary antibody against Ki67 
(Novocastra, Newcastle upon Tyne, UK). 
Tumorsphere culturing in vitro 
For generation of tumorspheres, single cells were 
plated on ultra-low attachment plates (Corning) in 
DMEM medium containing 20 ng/mL basic fibroblast 
growth factor (Sigma), 20 ng/mL EGF (Sigma), 4 
μg/mL heparin (Sigma) and B-27 supplement (1:50 
dilution, Invitrogen), and cultured at 37oC, 5% CO2. 
For limiting dilution experiments cells were plated in 
low attachment 96-well plates (Corning). For testing 
regeneration capacity of these tumorspheres, 
single-cell generated tumorspheres were collected by 
centrifugation (800 g) and then were mechanically and 
enzymatically dissociated in 0.25% Trypsin-EDTA for 
10 min at 37oC, followed by passing through 26G 
needles.  
Tumor injection 
Cells after trypsinization or cells immediately 
after sorting were resuspended in PBS, which then 
were mixed at 1:1 ratio with Matrigel (BD Biosciences) 
on ice. The cell mixture was then injected either 
subcutaneously bilaterally in the flanks and on the 
back or into the fourth mammary fat pad of female 
immunocompromised mice. At least five mice were 
used for each group. Mice were followed every other 
day for tumor formation. Tumor size was measured 
with a caliper when visible nodules were present. 
Tumor volume was calculated by using the formula 
V=2/3πrxryrz (r is radius and x, y, z refer to each axis, 
and π=3.14). 
3. Results  
BRCA1 mutant cancer cell lines and primary tumors 
from BRCA1 mutant mice contain a subpopulation of 
CD24+CD29+ cells  
We first tested whether CD24 and CD29, markers 
for normal mammary stem cells [15, 16], could be used 
to isolate CD24+CD29+ double positive populations 
from BRCA1 mutant tumor cells. We first performed 
flow cytometry analysis of two tumor cell lines derived 
from mammary tumors of Brca1Ko/Co;p53+/-;WAP-Cre 
mice [30]. We identified a subpopulation of cells in 
both cancer cell lines that expressed cell surface 
markers CD24 and CD29 (Fig. 1A). The profile was 
similar when cells were stained with CD49f instead of 
CD29 (Fig. 1C). CD49f stains for α6-integrin, which 
forms heterodimers with β1-integrin (CD29) and it has 
also been shown before to enrich for mammary stem 
cells [16]. We have also isolated a discrete 
subpopulation of CD24+CD29+ cells from BRCA1 
mutant primary mammary tumors after using 
antibodies against well-characterized endothelial 
(CD31) and hematopoietic (CD45 and TER119) Int. J. Biol. Sci. 2008, 4 
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antigens to deplete these lineage positive cells 
followed by fluorescence-activated cell sorting (FACS) 
( F i g .  1 D ) .  T h e  p e r c e n t a g e  o f  d o u b l e  p o s i t i v e  c e l l s  
varied among different BRCA1 cancer cell lines and 
primary tumors (12.8±2.5% in W0069, 16.7±5.3% in 
W780, and from 15-25% in the primary tumors). 
 
Figure 1. Both BRCA1 cancer cell lines and BRCA1 primary 
tumors contain a distinct subpopulation of CD24+CD29+ cells. 
(A, B) representative flow cytometry analysis of stained (A) and 
unstained (B) W0069 cells with CD24-PE and CD29-FITC. (C) 
representative flow cytometry analysis of W0069 cells stained 
with CD24-PE and CD49f-FITC. (D) representative flow 
cytometry analysis of CD31-, CD45-, Ter119- (Lin-) mammary 
epithelial cells purified from BRCA1 mammary tumors using 
anti CD24-PE and anti CD29-FITC. (E, F) representative flow 
cytometry analysis of two different subclones of W0069 cell 
line after staining with antibodies against CD24 and CD29 
[(subclone 228 (E), and subclone 229 (F)]. Numbers represent 
the percentage of each cell population. G) morphology of 
different cell lines under microscope.  
 
Because the CD24+CD29+ cells are only present 
as a small population in these cell lines and primary 
cancers, we next investigated whether this population 
of cells can be enriched in the subclones derived from 
these cells. Therefore, we derived subclones from one 
of the cell lines, W0069. Interestingly, we found that all 
clones examined exhibited heterogeneity containing 
from a high percentage of CD24+CD29+ cells at about 
15% (W0069-228, Fig. 1E) to very low or no 
CD24+CD29+ (W0069-229, Fig. 1F) cells as revealed by 
FACS analysis. While the profile of the W0069-228 
clone was similar to that of W0069, the W0069-229 
clone showed a homogeneous profile by flow 
cytometry where we could not detect discrete cell 
populations of double positive cells.  Notably, there 
was a difference in cellular morphology between the 
different subclones as well. The morphology of the 
W0069-228 subclone was similar to the parental cells 
characterized by a heterogeneous population of cells 
with different shapes as compared with the 
homogeneous population of W0069-229 (Fig. 1G). 
Thus, the heterogeneity found by FACS analysis was 
reflected in the morphology of these cell lines as 
observed by microscopy. Since these clones were 
derived from individual single cells, the failure to 
obtain a high purity of CD24+CD29+ cells suggests 
that these cells might differentiate and repopulate the 
heterogeneity, while the CD24-CD29- cells, such as 
W0069-229 might have a decreased ability to undergo 
differentiation, and therefore maintain their 
homogeneity (see next for further evidence).  
The differences in the number of CD24+CD29+ 
cells in subclones led us to test whether there are any 
different phenotypes between these clones. 
Specifically, we were interested in characteristics 
related to cancer stem cell phenotype such as the 
ability to proliferate or grow under low attachment 
conditions either in liquid culture or in matrigel. The 
proliferation capacity correlated with the amount of 
double positive cells since both W0069 and W0069-228 
cells proliferated much faster than W0069-229 cells 
(Fig. 2A, B). Furthermore, both W0069 and W0069-228 
c o u l d  f o r m  c o l o n i e s  i n  s o f t  a g a r  a n d  m a t r i g e l ,  
respectively, while no colonies were formed when the 
same number of W0069-229 cells was tested under 
identical experimental conditions (Fig. 2C, D). To 
determine the tumor-initiating capacity of the cell 
lines, we injected subclones containing different 
percentages of double positive cells to nude mice 
subcutaneously and monitored tumor formation. 
W0069-228 cells showed enhanced tumorigenicity 
compared to W0069-229 cells as indicated by 
measuring the tumor volume at different time points 
after injection (Fig. 3A). This was further confirmed by 
staining tumors with the proliferation marker Ki67, 
since it was shown that in W0069-228 tumors the 
majority of cells exhibited positive staining compared Int. J. Biol. Sci. 2008, 4 
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to the lower amount of Ki67 positive cells found in 
W0069-229 tumors (61±4.9% vs. 34±1.1%, respectively), 
suggesting that indeed W0069-228 cells are more 
tumorigenic than W0069-229 cells (Fig. 3B). The same 
results were obtained when the different cell lines 
were injected directly to the mammary fat pad of nude 
mice. After 106 cells of either W0069 or W0069-228 cells 
were injected, all mice formed tumors (6/6) in both 
cases after one month. On the other hand, when 
W0069-229 cells were injected, only half of the mice 
(3/6) formed tumors. In addition, tumors generated 
from W0069 and W0069-228 cells were much larger 
(>1cm) than tumors formed from the same number of 
W0069-229 cells (<0.5cm) when the tumors were 
measured one month after injection (Fig. 3C). Based on 
previous studies it is believed that tumors are 
composed of a heterogeneous population of cells, with 
differences in their phenotypic characteristics and 
proliferative potential, including cancer cells with 
indefinite proliferative potential and those with 
limited or no proliferative potential [11, 31]. Thus, our 
data indicates that the presence of CD24+CD29+ cells 
may drive tumorigenicity of these cell lines, implying 
that this subpopulation shares the characteristics of 
cancer initiating cells. 
 
 
Figure 2. CD24+CD29+ cells affect characteristics of cancer 
cell lines including proliferation and anchorage-independent 
growth. (A) W0069, W0069-228, and W0069-229 cells were 
grown for 72h and cell proliferation was assessed by MTT assay 
at 24h, 48h and 72h, respectively. (B) 5x10
4 cells for each cell 
line were grown in 6 well plates. Every 24h cells were collected 
and the number of cells was measured by using Z1 Coulter 
counter up to 8 days. (C, D) cells were grown either in soft agar 
(C) or in matrigel (D), respectively. Numbers represent the 
number of colonies in one out of three independent experiments. 
Characteristic pictures of colonies in both soft agar and matrigel 
are shown on the right.  
 
Figure 3. Enhanced tumorigenicity in the presence of 
CD24+CD29+ cells. (A) 10
6 cells were injected subcutaneously 
and tumor size was measured with a caliper. Tumor volume is 
expressed in mm
3 by using the formula mentioned in the 
Materials and Methods. (B) Paraffin-embedded sections of 
tumors were stained with hematoylin-eosin (H&E) or with an 
antibody recognizing the Ki67 antigen. (C) 10
6 cells were 
injected into the fourth mammary fat pad and mice were 
monitored for tumor formation for 30 days after injection. 
Denominators in the table represent the number of injections, 
and numerators represent the number of resultant tumors. 
 
Double positive (CD24+CD29+) cells exhibit 
differentiation potential 
To provide further evidence to our hypothesis, 
we sorted out CD24 and CD29 double positive or 
negative cells and compared their ability for growth, 
differentiation, and tumorigenesis. After 2-3 passages 
in conventional tissue culture dishes, the sorted 
CD24+CD29+ cells were able to differentiate and 
reconstitute the heterogeneity found in the parental 
cell line, as revealed by FACS using markers for either 
CD24/CD29 (Fig. 4A) or CD24/CD49f (Fig. 4B). In 
contrast, the sorted CD24-CD29- cells could not Int. J. Biol. Sci. 2008, 4 
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differentiate and reconstitute the heterogeneity found 
in the W0069 cell line (Fig 4C, D). Notably, the 
heterogeneity of the double positive cells was again 
reflected in the morphology of the cells in culture (Fig. 
4E), which was similar to the parental cell line. On the 
other hand, double negative cells in culture were 
homogeneous and looked very similar to the 
W0069-229 subclone. Thus, expansion of double 
positive cells in a monolayer leads to reconstitution of 
all different subpopulations found in parental cells, 
whereas cells depleted of double positive cells were 
unable to repopulate the CD24+CD29+ fraction. 
 
Figure 4. CD24+CD29+ cells maintain their ability to 
differentiate. CD24+CD29+ cells were sorted out from the 
W0069 cell line and they were cultured as monolayers. After 3 
passages, flow cytometry analysis was performed using anti 
CD24-PE and anti CD29-FITC (A) or anti CD24-PE and anti 
49f-FITC (B). Same strategy was followed in the case of 
CD24-CD29- sorted out cells (C, D). Representative data after 
flow cytometry are shown. (E) morphology of double positive or 
double negative cell in culture under microscope.  
 
As mentioned earlier, one of the hallmarks of 
cancer stem cells is their ability to grow and form 
colonies under anchorage-independent conditions. 
Thus, in order to check whether double positive cells 
are enriched for cancer initiating cells, sorted 
CD24+CD29+ cells were grown in matrigel. As shown 
in figure 5A, and 5B, double positive cells exhibited 
enhanced colony-forming ability, whereas no colonies 
were formed when 500, 200, or 100 double negative 
cells were grown under the same experimental 
conditions. It was shown that epithelial cells grown in 
three-dimensional cultures recapitulate numerous 
features of breast epithelium in vivo, including the 
formation of acini-like spheroids, apicobasal 
polarization of cells, basal deposition of basement 
membrane components (collagen IV and laminin V), 
and in some cases, the production of milk proteins [32, 
33]. Since the cancer cell lines used were from 
mammary epithelial cancers, we wanted to investigate 
whether these cells may differentiate when cultured in 
three-dimensional cultures. Indeed we found that 
CD24+CD29+ cells exhibited an expanded 
differentiative repertoire compared to the double 
negative cells. While no differentiated structures were 
found in colonies formed by double negative cells, 
double positive cells could differentiate into complex 
tubular and branched structures reminiscent of the 
mammary ductal tree (Fig. 5C). Previous studies 
reported that normal mammary stem cells have the 
ability to recapitulate the architecture of the mammary 
gland [15, 34]. Since this subpopulation of cancer cells 
maintains the ability to differentiate in 
three-dimensional culture systems, it is possible that 
CD24+CD29+ cells share some of the characteristics of 
normal mammary stem cells.  
 
Figure 5. Double positive cells grow in three-dimensional 
cultures and form well differentiated structures. (A) 
Immediately after sorting, CD24+CD29+ and CD24-CD29- 
cells were grown in matrigel with varying number of cells per 
well. Numbers in table represent the number of colonies in one 
out of three independent experiments. (B) Pictures showing 
colonies formed when 1000 cells were inoculated in matrigel. 
Note, only one colony (arrow) was formed from 1000 double 
negative cells. (C) Characteristic colonies are shown in higher Int. J. Biol. Sci. 2008, 4 
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magnification. Arrows show differentiated structures as well as 
complex tubular structures formed from double positive cells 
grown in three dimensions. 
 
Double positive cells exhibit self-renewal capacity and 
contribute to tumor initiation and growth  
Most stem cell enrichment protocols rely on 
immunosorting according to the cell surface 
expression of some proteins. Alternatively, it has been 
shown that mammospheres, which are spherical 
colonies formed by epithelial cells when cultured on 
non-adherent surfaces are enriched in 
stem/progenitor cells [35]. Since cancer initiating cells 
resemble stem cells in their ability to grow as 
“ t u m o r s p h e r e s ”  i n  c u l t u r e ,  w e  w a n t e d  t o  c h e c k  
whether CD24+CD29+ cells maintain the potential to 
grow under conditions in which they cannot attach to 
a solid substratum. Whereas many cells underwent 
anoikis as expected, both parental and double positive 
cells were able to form “tumorspheres” after 3-4 days 
in culture (Fig. 6A). After enzymatic dissociation of 
these spheres, we could still get secondary 
“tumorspheres”, indicating that they are enriched for 
cancer initiating cells with self-renewal capacity. In 
contrast, the majority of double negative cells grown in 
suspension were non-viable floating cells with some 
cells growing as aggregates, which eventually 
deteriorated. To further confirm that these 
tumorspheres represented the progeny of an 
individual cell, we plated cells in limiting dilution with 
one cell, on the average, in each well of 96-well plates. 
Of note, we found that both parental and double 
positive cells had almost the same number of cells 
capable of giving rise to “tumorspheres” (419±96 vs. 
391±128 per 10000 cells), while no tumorsphere was 
found in the double negative cells (Fig. 6B).  
Nevertheless, the most important feature of 
cancer stem cells is their ability to form tumors. For 
this reason we sorted out double positive and double 
negative cells from primary BRCA1 tumors developed 
in Brca1Co/Co;p53+/-;MMTV-Cre mice [28] and tested their 
tumor forming ability. When as low as 500 
CD24+CD29+ cells were injected into the mammary fat 
pad immediately after sorting, these cells were able to 
form tumors (4/5 injections), whereas no tumor 
formation was seen in mammary fat pads injected with 
500 double negative cells (Fig. 6C). Notably, tumors 
grown from CD24+CD29+ cells showed a 
phenotypical heterogeneity when they were checked 
by flow cytometry, since both double positive and 
double negative cells were present in these tumors 
resembling the profile of the primary tumors (data not 
shown). These results suggest that double positive 
cells share some of the characteristics of cancer stem 
cells, since they exhibit the capacity for self-renewal, 
differentiation and the ability to form tumors in vivo. 
 
Figure 6. Enhanced self-renewal capacity and tumor growth 
ability of CD24+CD29+ cells compared to double negative 
cells. (A) morphology of tumorspheres grown in ultra-low 
attachment plates from W0069 cells, CD24+CD29+, and 
CD24-CD29- cells in culture. CD24-CD29- cells can form small 
cell aggregates but they cannot form tumorspheres. (B) 
Quantification of tumorsphere initiating cells was done by 
performing limiting dilution assay after plating 1 cell/well in 96 
well plates. (C) CD24+CD29+ and CD24-CD29- cells were 
sorted out from primary BRCA1 tumors. Immediately after 
sorting, 500 cells from each group were injected into the fourth 
mammary fat pad of nude mice. Denominators in the table 
represent the number of injections, and numerators represent the 
number of resultant tumors. Tumor growth rates were monitored 
as described in Materials and Methods and average tumor size is 
shown. 
4. Discussion 
Recently a subpopulation (Lin-CD49fhiCD24med) 
was identified that is highly enriched for normal 
mammary stem cells by transplantation [15, 16]. After 
replacing CD49f with CD29 (β1-integrin), which forms 
heterodimers with α6-integrin (CD49f), a similar 
subpopulation (Lin-CD29hiCD24+) was also purified 
[15, 16]. Actually, a single cell with this phenotype can Int. J. Biol. Sci. 2008, 4 
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reconstitute a complete mammary gland in vivo, thus 
generating luminal and myoepithelial lineages as well 
as lobuloalveolar structures during pregnancy [15, 16]. 
If tumors originate from stem cells since normal stem 
cells may be the targets for transformation, it was 
hypothesized that it is possible that markers used for 
the isolation of normal mammary stem cells may also 
work for the isolation of mammary cancer stem cells 
[36]. In the present study, we tested this hypothesis 
and identified a subpopulation of mammary tumor 
initiating cells using markers such as CD24/CD29 or 
CD24/CD49f, which have been used to purify normal 
mammary stem cells. Thus, our study provides 
evidence for the first time that BRCA1-associated 
mammary cancer stem cells might originate from 
normal mammary stem cells. 
It was previously shown that mammary stem 
cells are Hoechst 33342 negative and Sca-1 positive 
[37]. However, recently it was found that a single cell 
with the phenotype CD24+CD29+ can reconstitute a 
complete mammary gland in vivo [15, 16]. 
Interestingly, neither high Sca-1 expression nor 
Hoechst33342 dye exclusion were enriched in this 
CD24 and CD29/CD49f population. Moreover, in 
contrast to a general concept that mammary stem cells 
divide slowly [38], the CD49fhiCD24med cells were 
found to be in G1 or S/G2/M fractions [16]. indicating 
that they are in a cycling, instead of quiescent, stage. 
Here we show that the amount of double positive cells 
in BRCA1 mutated cell lines correlates with the 
proliferative capacity, the ability to grow in 
anchorage-independent conditions and the 
tumor-forming ability of either these cell lines, or 
different subclones derived from the same cell lines. 
Furthermore, we proved that CD24+CD29+ cells retain 
their ability to proliferate and drive tumor formation 
by sorting out these cells from double negative cells. 
Indeed, we showed that CD24+CD29+ cells could 
repopulate the heterogeneity found in the parental 
cells, since different cell populations were found after 
2-3 passages in culture. Even more interestingly, the 
CD24+CD29+ cells could grow in three-dimensional 
culture systems, where differentiated structures were 
visible in contrast to double negative cells, suggesting 
that double positive cells might be less differentiated 
than CD24-CD29- cells. Thus, we conclude that 
CD24+CD29+ cells are enriched for cancer stem cells in 
BRCA1 deficient tumors. 
With the expansion of the cancer stem cell field 
many different markers for stem cells have been 
identified. Focusing on mammary/breast tumors, 
different markers have been described to enrich for 
cancer stem cells. For example, in MMTV-cNeu 
oncogene induced mammary tumors, cancer-initiating 
cells were found exclusively in either Sca1+CD24+ or 
Sca1-CD24+ populations [39], whereas in 
MMTV-Wnt1 mammary tumors, Thy+CD24+ were 
highly enriched for cells capable of regenerating new 
tumors [40]. On the other hand, in breast tumors, it has 
been shown that CD44+CD24Low cells share 
characteristics of cancer stem cells [17]. These 
differences may imply that in different kind of tumors, 
different cells are the targets for transformation, thus 
different markers are needed for the isolation of the 
specific tumorigenic subpopulation. Of note, even in 
tumors caused by a mutation of the same tumor 
suppressor gene, there is a discrepancy in the 
phenotype of this specific subpopulation, as it was 
recently shown that BRCA1 mutant tumors contain 
distinct CD44+CD24- and CD133+ populations with 
cancer stem cell characteristics [41]. Given that in our 
study we showed that CD24+CD29+ cells are enriched 
for cancer initiating cells, it is possible that different 
markers may be expressed in stem cells at different 
stages of differentiation within the same tumor. Thus, 
by using different markers we may isolate primitive 
cancer stem cells, early progenitors, or differentiated 
progenitors. All of these cells may drive tumor 
formation, but they can differ in other aspects, such as 
the capacity for self-renewal, differentiation potential, 
or metastatic ability. Thus, although there has been 
dramatic progress in the breast cancer stem cell field, 
future studies are needed to find out which markers 
stain what types of cells, in order to further define the 
heterogeneity exhibited by cancer stem/precursor 
cells. 
Our data suggest that during BRCA1 related 
tumorigenesis, normal stem cells may be the targets for 
transformation and tumor formation as it has been 
shown recently for MMTV-Wnt1 mammary tumors 
[40]. The self-renewal and differentiation capacity of 
these cells in non-adherent conditions supports the 
idea that although these cells have been transformed to 
cancer cells they still maintain many of the 
characteristics of normal stem cells. We propose that 
our data provides evidence of the cancer stem cell 
origin of BRCA1 tumors. Although recent data from 
human samples suggest that BRCA1 plays a role in the 
differentiation of normal breast stem cells [21, 23], its 
exact role in cancer stem cells remains to be elucidated. 
In this context we believe that 
Brca1Co/Co;p53+/-;MMTV-Cre mice should serve as a 
powerful tool to dissect the role of BRCA1 in the 
cancer initiating cells and provide insights into 
development and treatment of breast cancer 
specifically in BRCA1 mutation carriers. 
Acknowledgements 
We gratefully acknowledge members of the Deng Int. J. Biol. Sci. 2008, 4 
 
141
laboratory for helpful discussion, and Drs. J. Tyler 
Lahusen and C. Xiao for critical reading of the 
manuscript. This work was supported by the 
Intramural Research Program of the National Institute 
of Diabetes, Digestive and Kidney Diseases, National 
Institutes of Health, USA. 
Conflict of interest 
The authors have declared that no conflict of 
interest exists. 
References 
1.   Alberg AJ, Lam AP, Helzlsouer KJ. Epidemiology, prevention, 
and early detection of breast cancer. Curr Opin Oncol. 1999; 11: 
435-441. 
2.  Brody LC, Biesecker BB. Breast cancer susceptibility genes. 
BRCA1 and BRCA2. Medicine (Baltimore). 1998; 77: 208-226. 
3.  Eccles DM, Pichert G. Familial non-BRCA1/BRCA2-associated 
breast cancer. Lancet Oncol. 2005; 6: 705-711. 
4.  Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA 
Cancer J Clin. 2007; 57: 43-66. 
5.   Zhang J, Powell SN. The role of the BRCA1 tumor suppressor in 
DNA double-strand break repair. Mol Cancer Res. 2005; 3: 
531-539. 
6.  Kang SP, Martel M, Harris LN. Triple negative breast cancer: 
current understanding of biology and treatment options. Curr 
Opin Obstet Gynecol. 2008; 20: 40-46. 
7.  Rodriguez-Pinilla SM, Sarrio D, Honrado E, et al. Prognostic 
significance of basal-like phenotype and fascin expression in 
node-negative invasive breast carcinomas. Clin Cancer Res. 
2006; 12: 1533-1539. 
8.  Banerjee S, Reis-Filho JS, Ashley S, et al. Basal-like breast 
carcinomas: clinical outcome and response to chemotherapy. J 
Clin Pathol. 2006; 59: 729-735. 
9.  Song LL, Miele L. Cancer stem cells--an old idea that's new 
again: implications for the diagnosis and treatment of breast 
cancer. Expert Opin Biol Ther. 2007; 7: 431-438. 
10. Pina C, Enver T. Differential contributions of haematopoietic 
stem cells to foetal and adult haematopoiesis: insights from 
functional analysis of transcriptional regulators. Oncogene. 2007; 
26: 6750-6765. 
11. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and 
cancer stem cells. Nature. 2001; 414: 105-111. 
12. Hennighausen L, Robinson GW. Think globally, act locally: the 
making of a mouse mammary gland. Genes Dev. 1998; 12: 
449-455. 
13. Villadsen R, Fridriksdottir AJ, Ronnov-Jessen L, et al. Evidence 
for a stem cell hierarchy in the adult human breast. J Cell Biol. 
2007; 177: 87-101. 
14. Kordon EC, Smith GH. An entire functional mammary gland 
may comprise the progeny from a single cell. Development. 
1998; 125: 1921-1930. 
15. Shackleton M, Vaillant F, Simpson KJ, et al. Generation of a 
functional mammary gland from a single stem cell. Nature. 2006; 
439: 84-88. 
16. Stingl J, Eirew P, Ricketson I, et al. Purification and unique 
properties of mammary epithelial stem cells. Nature. 2006; 439: 
993-997. 
17. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective 
identification of tumorigenic breast cancer cells. Proc Natl Acad 
Sci U S A. 2003; 100: 3983-3988. 
18. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate 
for the breast and ovarian cancer susceptibility gene BRCA1. 
Science. 1994; 266: 66-71. 
19. Deng CX. BRCA1: cell cycle checkpoint, genetic instability, DNA 
damage response, and cancer evolution. Nucleic Acids Res. 
2006; 34: 1416-1426, Deng CX Tumor formation in Brca1 
conditional mutant mice. Environ Mol Mutagen. 2002; 39: 
171-177. 
20. Asselin-Labat ML, Shackleton M, Stingl J, et al. Steroid hormone 
receptor status of mouse mammary stem cells. J Natl Cancer 
Inst. 2006; 98: 1011-1014. 
21. Foulkes WD. BRCA1 functions as a breast stem cell regulator. J 
Med Genet. 2004; 41: 1-5. 
22. Li W, Xiao C, Vonderhaar BK, et al. A role of estrogen/ERalpha 
signaling in BRCA1-associated tissue-specific tumor formation. 
Oncogene. 2007; 26: 7204-7212. 
23. Liu S, Ginestier C, Charafe-Jauffret E, et al. BRCA1 regulates 
human mammary stem/progenitor cell fate. Proc Natl Acad Sci 
U S A. 2008; 105: 1680-1685. 
24. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast 
and ovarian cancer associated with BRCA1 or BRCA2 mutations 
detected in case Series unselected for family history: a combined 
analysis of 22 studies. Am J Hum Genet. 2003; 72: 1117-1130. 
25. Jernstrom H, Lubinski J, Lynch HT, et al. Breast-feeding and the 
risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J 
Natl Cancer Inst. 2004; 96: 1094-1098. 
26. Bonnet D, Dick JE. Human acute myeloid leukemia is organized 
as a hierarchy that originates from a primitive hematopoietic 
cell. Nat Med. 1997; 3: 730-737. 
27. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human 
acute myeloid leukaemia after transplantation into SCID mice. 
Nature. 1994; 367: 645-648. 
28. Xu X, Wagner KU, Larson D, et al. Conditional mutation of Brca1 
in mammary epithelial cells results in blunted ductal 
morphogenesis and tumour formation [see comments]. Nat 
Genet. 1999; 22: 37-43. 
29. Deng CX, Xu X. Generation and analysis of Brca1 conditional 
knockout mice. Methods Mol Biol. 2004; 280: 185-200. 
30. Brodie SG, Xu X, Qiao W, et al. Multiple genetic changes are 
associated with mammary tumorigenesis in Brca1 conditional 
knockout mice. Oncogene. 2001; 20: 7514-7523. 
31. Pardal R, Clarke MF, Morrison SJ. Applying the principles of 
stem-cell biology to cancer. Nat Rev Cancer. 2003; 3: 895-902. 
32. Petersen OW, Ronnov-Jessen L, Howlett AR, et al. Interaction 
with basement membrane serves to rapidly distinguish growth 
and differentiation pattern of normal and malignant human 
breast epithelial cells. Proc Natl Acad Sci U S A. 1992; 89: 
9064-9068. 
33. Gudjonsson T, Ronnov-Jessen L, Villadsen R, et al. Normal and 
tumor-derived myoepithelial cells differ in their ability to 
interact with luminal breast epithelial cells for polarity and 
basement membrane deposition. J Cell Sci. 2002; 115: 39-50. 
34. Zucchi I, Sanzone S, Astigiano S, et al. The properties of a 
mammary gland cancer stem cell. Proc Natl Acad Sci U S A. 
2007; 104: 10476-10481. 
35. Dontu G, Abdallah WM, Foley JM, et al. In vitro propagation and 
transcriptional profiling of human mammary stem/progenitor 
cells. Genes Dev. 2003; 17: 1253-1270. 
36.  Wang RH. The new portrait of mammary gland stem cells. Int J 
Biol Sci. 2006; 2: 186-187. 
37.  Welm B, Behbod F, Goodell MA, et al. Isolation and 
characterization of functional mammary gland stem cells. Cell 
Proliferation. 2003; 36(Suppl 1):17-32. 
38. Welm BE, Tepera SB, Venezia T, et al. Sca-1(pos) cells in the 
mouse mammary gland represent an enriched progenitor cell 
population. Dev Biol. 2002; 245: 42-56. 
39. Liu JC, Deng T, Lehal RS, et al. Identification of tumorsphere- and 
tumor-initiating cells in HER2/Neu-induced mammary tumors. 
Cancer Res. 2007; 67: 8671-8681. 
40. Cho RW, Wang X, Diehn M, et al. Isolation and molecular 
characterization of cancer stem cells in MMTV-Wnt-1 murine Int. J. Biol. Sci. 2008, 4 
 
142
breast tumors. Stem Cells. 2008; 26: 364-371. 
41. Wright MH, Calcagno AM, Salcido CD, et al. Brca1 breast tumors 
contain distinct CD44+/CD24- and CD133+ cells with cancer 
stem cell characteristics. Breast Cancer Res. 2008; 10: R10. 